NCT03378011

Brief Summary

evaluate the effect of UVA1 phototherapy in the treatment of acral vitiligo.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2015

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

December 8, 2017

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 19, 2017

Completed
Last Updated

December 19, 2017

Status Verified

December 1, 2017

Enrollment Period

1 year

First QC Date

December 8, 2017

Last Update Submit

December 17, 2017

Conditions

Acral Vitiligo

Outcome Measures

Primary Outcomes (1)

  • effect of medium dose UVA1 phototherapy in treatment of acral vitiligo

    effect of medium dose UVA1 phototherapy in treatment of acral vitiligo using point counting and vitiligo area severity index (VASI) score

    1 year

Study Arms (2)

UVA1 phototherapy

ACTIVE COMPARATOR

UVA1 phototherapy in acral vitiligo

Other: phototherapy

Topical PUVA

ACTIVE COMPARATOR

Topical PUVA in acral vitiligo

Other: phototherapy

Interventions

phototherapyOTHER

phototherapy either UVA1 or topical PUVA on acral vitiligo

Topical PUVAUVA1 phototherapy

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with acral vitiligo.
  • Patients more than 12 years old.

You may not qualify if:

  • Patients less than 12 years old.
  • Patients with any other skin diseases or autoimmune diseases.
  • Patients taking medical treatment or phototherapy for vitiligo.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maha Fathy Elmasry

Cairo, Egypt

Location

MeSH Terms

Interventions

Phototherapy

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Maha Elmasry

    Cairo University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

December 8, 2017

First Posted

December 19, 2017

Study Start

November 1, 2015

Primary Completion

November 1, 2016

Study Completion

November 1, 2016

Last Updated

December 19, 2017

Record last verified: 2017-12

Locations

EG(1)